drugset / Trial / NCT02454556
A Randomized, Multicentre, Open Label, Evaluator Blinded Study to Evaluate Safety and Efficacy of Folitime® of Gemabiotech S.A., Versus Gonal-f ® of Merck Serono, in Patients With Infertility Undergoing ART
Phase 3
Completed
106 enrolled
Gema Biotech S.A.
QUID Quality in Drugs and Devices Latin American Consulting SRL · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
This is an open-label, Phase 3, randomized, two arms, multicenter, prospective, experimental study of Folitime® (a new biosimilar formulation of r-hFSH, follitropin alfa) versus the original one (Gonal-f ®).
Timeline
- Start
- 2015-04
- Primary completion
- 2016-12
- Completion
- 2016-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gonal-f | Protein / enzyme biologic | 225 iu | Subcutaneous |